New funding emerges as biotech VC deals fade
This article was originally published in Scrip
Executive Summary
Venture capitalists are putting less money in biotechnology, but that hasn't stopped drug developers from raising new cash whether it's from the handful of surviving VC firms with life science interests, from pharmaceutical partners and corporate venture funds, or from stock market investors.